Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Venetoclax in AML updates: approval & combinations

The FDA recently approved venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine for the treatment of newly diagnosed adult acute myeloid leukemia (AML). Here, Marina Konopleva, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, presents the results of the Phase II study of venetoclax with 10-day decitabine (NCT03404193), as well as an ongoing study of venetoclax plus the MDM2 inhibitor idasanutlin. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.